60 DEGREES PHARMACEUTICALS, INC. Prospectus Supplement (Debt Securities)
60 Degrees Pharmaceuticals amends its at-the-market program to register up to $1,308,000 of common stock pursuant to its September 5, 2025 Sales Agreement with H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
60 Degrees Pharmaceuticals amends its at-the-market program to register up to $1,308,000 of common stock pursuant to its September 5, 2025 Sales Agreement with H.C. Wainwright & Co., LLC.
The prospectus supplement updates the aggregate offering capacity to $1,308,000, excluding 555,593 shares previously sold for aggregate gross proceeds of $1,396,091. It states a public float of approximately $8,112,998 based on 1,581,682 shares outstanding as of January 28, 2026 and notes a one-for-four reverse stock split effective January 20, 2026. The filing cites the Form S-3 limitation that sales will not exceed one-third of public float in a 12-month period.
Insights
ATM increase adds incremental capacity but remains administratively routine.
The supplement raises the at-the-market registration to $1,308,000 under the Sales Agreement dated September 5, 2025, and excludes 555,593 shares previously sold for $1,396,091. The filing reiterates the Form S-3 constraint limiting primary public offerings to one-third of the public float while the public float is below $75.0 million.
Key dependencies include market demand and holder decisions; cash-flow treatment is issuer proceeds from primary sales. Timing and execution details are governed by the Sales Agent agreement and are not specified in this excerpt.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-280796
PROSPECTUS SUPPLEMENT
(to Prospectus Supplement dated September 5, 2025
and Prospectus dated July 18, 2024)
Up to $1,308,000
60 Degrees Pharmaceuticals, Inc.
Common Stock
This prospectus supplement (the “Prospectus Supplement”) amends and supplements the prospectus supplement dated September 5, 2025, and its accompanying base prospectus dated July 18, 2024 (collectively, the “ATM Prospectus”), relating to the offer and sale of shares of our common stock from time to time pursuant to the terms of At The Market Offering Agreement dated September 5, 2025 (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Sales Agent”), acting as sales agent or principal. This Prospectus Supplement should be read in conjunction with the ATM Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus. This Prospectus Supplement is not complete without and may only be delivered or utilized in connection with the ATM Prospectus, and any future amendments or supplements thereto.
We are filing this Prospectus Supplement to amend the ATM Prospectus to update the amount of shares of our common stock we may offer and sell to or through the Sales Agent pursuant to the Sales Agreement to $1,308,000, which does not include the 555,593 of shares that were previously sold for aggregate gross proceeds of $1,396,091 pursuant to the Sales Agreement under the ATM Prospectus as of the date of this Prospectus Supplement.
As of January 28, 2026, our public float, which is equal to the aggregate market value of our outstanding voting and non-voting common stock, held by non-affiliates, was approximately $8,112,998, based on 1,581,682 shares of outstanding common stock, of which approximately 1,560,192 shares were held by non-affiliates, and a closing sale price of our common stock of $5.20 on that date. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering under the registration statement of which this Prospectus Supplement and the ATM Prospectus forms a part with a value exceeding more than one-third of our public float in any 12-calendar-month period so long as our public float remains below $75.0 million. As of the date hereof, we have offered and sold $1,396,091 of shares of our common stock pursuant to General Instruction I.B.6 of Form S-3 during the prior 12-calendar month period that ends on and includes the date hereof.
On January 20, 2026, we effected a reverse stock split of our outstanding common stock at a ratio of one-for-four (1:4). All share information presented in this Prospectus Supplement gives effect to this reverse stock split.
Our common stock is listed on The Nasdaq Capital Market under the symbol “SXTP.” The last reported sale price of our common stock on The Nasdaq Capital Market on February 27, 2026, was $3.11 per share.
INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE “RISK FACTORS” BEGINNING ON PAGE S-20 OF THE ATM PROSPECTUS AND IN THE DOCUMENTS INCORPORATED BY REFERENCE IN THE REGISTRATION STATEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR COMMON STOCK.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement and the accompanying prospectus. Any representation to the contrary is a criminal offense.
H.C. Wainwright & Co.
The date of this prospectus supplement is March 2, 2026